Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PPD Names New Senior Vice President For Global Regulatory Affairs
Dr Ukwu is expected to take up the responsibilities for all regulatory services of the company and will also provide clinical vaccine expertise to advance the company’s vaccines
Dr Ukwu is expected to take up the responsibilities for all regulatory services of the company and will also provide clinical vaccine expertise to advance the company’s vaccines
Axxess Pharma said that Fortex drug is indicated for the relief of pain and inflammation of musculoskeletal conditions such as arthritis and muscle soreness. As per a license
Watson andItero said that rFSH is currently in preclinical development as a biosimilar molecule for the treatment of female infertility. As per the terms of the agreement, Itero
The patent covers all compositions of matter and methods of use for NVC-612 and related compounds. NovaBay said that the new patent will broaden protection for NovaBay’s Aganocide
Voreloxin is an anticancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer, where as Cytarabine is the standard-of-care
PharmaPros is expected to provide additional services to support both EDC and paper based studies using its proprietary methodology: electronic Data Lifecycle Management (eDLM) in conjunction with Dataflow
Mr Peacock is expected to take up the responsibility for Amgen’s finance and investor relations operations. Most recently, Mr Peacock has served as the CFO and administration officer
Access Pharma and the biotechnology company are expected to develop the product with the use of its proprietary Cobalamin Oral Drug Delivery Technology, which utilises the body’s natural
Earlier, on July 12, 2010, Endo Pharma has acquired HealthTronics through a tender offer and subsequent merger upon which HealthTronics became a wholly owned subsidiary of Endo Pharma.
As per the terms of the merger agreement, Carlyle is expected to acquire all of the outstanding common shares of NBTY for $55 per share in cash, representing